Texas Permanent School Fund Has $2.68 Million Stock Position in Haemonetics Co. (NYSE:HAE)

Posted by on May 10th, 2023

Texas Permanent School Fund lowered its position in shares of Haemonetics Co. (NYSE:HAE – Get Rating) by 7.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 34,023 shares of the medical instruments supplier’s stock after selling 2,886 shares during the quarter. Texas Permanent School Fund owned 0.07% of Haemonetics worth $2,676,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the company. Wellington Management Group LLP boosted its position in Haemonetics by 21.5% during the 1st quarter. Wellington Management Group LLP now owns 6,165,363 shares of the medical instruments supplier’s stock worth $389,776,000 after acquiring an additional 1,091,484 shares during the last quarter. Capital Research Global Investors raised its stake in shares of Haemonetics by 166.1% during the 1st quarter. Capital Research Global Investors now owns 5,452,006 shares of the medical instruments supplier’s stock worth $344,676,000 after purchasing an additional 3,402,873 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Haemonetics by 3.4% during the 3rd quarter. Vanguard Group Inc. now owns 5,195,195 shares of the medical instruments supplier’s stock worth $384,600,000 after purchasing an additional 173,113 shares in the last quarter. Neuberger Berman Group LLC raised its stake in shares of Haemonetics by 4.7% during the 3rd quarter. Neuberger Berman Group LLC now owns 3,893,389 shares of the medical instruments supplier’s stock worth $288,209,000 after purchasing an additional 174,545 shares in the last quarter. Finally, Royce & Associates LP raised its stake in shares of Haemonetics by 3.9% during the 3rd quarter. Royce & Associates LP now owns 874,808 shares of the medical instruments supplier’s stock worth $64,762,000 after purchasing an additional 33,223 shares in the last quarter.

Haemonetics Stock Down 0.5 %

HAE stock opened at $81.40 on Wednesday. The company has a debt-to-equity ratio of 0.98, a current ratio of 3.11 and a quick ratio of 1.99. The stock has a market capitalization of $4.11 billion, a price-to-earnings ratio of 44.00, a PEG ratio of 2.50 and a beta of 0.44. The business’s fifty day moving average price is $80.88 and its two-hundred day moving average price is $81.60. Haemonetics Co. has a fifty-two week low of $50.48 and a fifty-two week high of $91.39.

Haemonetics (NYSE:HAE – Get Rating) last posted its quarterly earnings data on Tuesday, February 7th. The medical instruments supplier reported $0.85 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.06. The firm had revenue of $305.30 million for the quarter, compared to analysts’ expectations of $300.47 million. Haemonetics had a return on equity of 19.84% and a net margin of 8.48%. The company’s quarterly revenue was up 17.5% compared to the same quarter last year. During the same quarter last year, the business earned $0.84 EPS. On average, equities analysts anticipate that Haemonetics Co. will post 2.94 earnings per share for the current year.

Analyst Upgrades and Downgrades

HAE has been the topic of a number of analyst reports. Barrington Research upped their price objective on Haemonetics from $94.00 to $103.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 8th. Morgan Stanley upped their price objective on Haemonetics from $84.00 to $88.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 8th. Citigroup dropped their price target on Haemonetics from $95.00 to $90.00 in a research note on Monday, April 3rd. Mizuho increased their price target on Haemonetics from $110.00 to $115.00 and gave the company a “buy” rating in a research note on Wednesday, February 8th. Finally, StockNews.com assumed coverage on Haemonetics in a research note on Thursday, March 16th. They issued a “buy” rating on the stock. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, Haemonetics has a consensus rating of “Moderate Buy” and a consensus target price of $100.17.

Haemonetics Profile

(Get Rating)

Haemonetics Corp. is a global healthcare company, which engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, Hospital, and Corporate. The Plasma segment offers automated plasma collection and donor management software systems.

Read More

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAE – Get Rating).

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.